Histopathological Confirmation Research Articles

Clinical profile and outcomes of patients with endometrial cancer from Northwest India: A retrospective study

ABSTRACT Background: Endometrial cancer is a significant health concern, but there is a lack of region-specific data on its clinical profile and outcomes in Northwest India. Recognizing the importance of early diagnosis and the evolving landscape of precision oncology, the study incorporated risk stratification based on established guidelines and updated staging. Objectives: The primary objective of the study was to determine the clinicopathological profile of patients with endometrial cancer. The secondary objectives were to estimate the survival outcomes, disease-free survival (DFS), and overall survival (OS) based on various staging protocols. Materials and Methods: We included patients with biopsy-confirmed carcinoma of the endometrium, managed at Mohan Dai Oswal Hospital, Ludhiana, Punjab from January 1, 2017 to August 31, 2022. Retrospective data were collected from electronic medical records and patient outpatient department files after ethics committee approval. The data were stratified according to the 2014 consensus guidelines of the European Society of Medical Oncology, the European Society of Gynecological Oncology, and the European Society for Radiotherapy and Oncology as well as the 2023 staging guidelines from the international federation of gynecology and obstetrics for analysis. Survival was calculated from histopathology confirmation to progression, death, or last follow-up. Statistical analysis was performed using Statistical Package for the Social Sciences (SPSS) v22, with Kaplan-Meier for survival estimates, Cox regression for survival associations, and log-rank tests for group comparisons. Results: We included a total of 111 patients. The median age of the subjects was 64 years (range 37-88). Surgery was the primary treatment in 109 (98.7%). The 5-year OS and DFS rates were 85.6% and 75.7%, respectively, with high-risk patients showing worse outcomes (3-year OS: 75.2%; 4-year OS: 37.6%) compared to low/intermediate-risk patients (5-year OS: 100%, P < 0.001). Conclusion: This study highlights significant survival variations based on risk stratification in endometrial cancer, underscoring the need for tailored management approaches.

Isolation and Identification Of Candida Albicans In Smokers With Epithelial Dysplasia And Squamous Cell Carcinoma: A Histopathological Correlation

Background:Greater adaptability of Candida to the host niche makes it the most common opportunistic pathogen. Its role as a commensal or pathogen in development of premalignancies and its progression to malignancies is of considerable debate. Present study was undertaken to determine the role of Candida albicans(CA)in progressionof oral cancer by isolation and identification by mycological methods in smokers without oral lesions and histopathologically diagnosed cases of epithelial dysplasia (ED) and oral squamous cell carcinoma (OSCC). Methodology:The study comprised of 120 cases that included study group of 40 smokers with oral lesions, 40 smokers without oral lesions and 40 non-smokers as control group. Clinical examination was followed by oral rinse sample collection and biopsy for histopathological confirmation. Sedimented oral rinse was inoculated on Sabouraud’s dextrose agar (SDA). Isolated Candida colony after identification with Gram stain was subjected to germ tube and chlamydospore formation test for confirmation of CA. The data was statistically analysed using chi square test. Results:Colonisation of CA was 52.5% in the study group and 5% in the control group, was found to be statistically significant (p<0.001).Association of CA in smokers with varying histopathologic grades of oral lesions showed no evidence of a correlation. However, positive correlation was found in OSCC (n=19, 95%) and showed statistical significance (p<0.001). Conclusion:The present study showed an increase in colonization of CA in malignant lesions suggesting that CA in conjunction with tobacco usage may play a role in oral carcinogenesis.

A Narrative Review of the Evolution of Diagnostic Techniques and Treatment Strategies for Acral Lentiginous Melanoma.

Acral melanoma (AM) is a subtype of cutaneous melanoma located on the palms, soles, and nails. The pathogenesis of AM involves mechanical stimulation and characteristic tumor-promoting mutations, such as those in the KIT proto-oncogene. Dermoscopy is useful for diagnosing AM, which is characterized by parallel ridge patterns and irregular diffuse pigmentation. Although histopathological confirmation is the gold standard for diagnosing AM, lesions showing minimal histopathological changes should be considered early-stage AM if they clinically resemble it. Recently, immunohistochemical staining of preferentially expressed antigen in melanoma has been recognized as a useful method to distinguish benign from malignant melanocytic tumors. Research reveals that AM is associated with an immunosuppressive microenvironment characterized by increased numbers of M2 macrophages and regulatory T cells, alongside a decreased number of tumor-infiltrating lymphocytes. Mohs micrographic surgery or digit-sparing wide local excision has been explored to improve quality of life and replace wide local excision or proximal amputation. AM has a worse prognosis than other subtypes, even in the early stages, indicating its inherent aggressiveness.

Microbiology of Actinomyces Species Isolated From Patients With Invasive Disease and Contaminated Samples in a Comprehensive Cancer Center.

Actinomyces are mucous membrane commensals that infrequently cause invasive disease. Our goal was to define Actinomyces species prevalence, the predominant disease site and risk factors for actinomycosis. We retrospectively reviewed patients with growth of Actinomyces species from cultures in a single-cancer center from July 2007 to June 2020. Proven invasive actinomycosis was defined as the presence of compatible clinical syndrome and radiographic findings with histopathological confirmation or culture from a normally sterile site. Probable invasive actinomycosis was defined based on the same criteria but without histologic confirmation. Contaminants were defined as culture growth in the absence of clinical or radiological findings consistent with disease. Speciation of Actinomyces was performed by the bioMerieux VITEK 2 anaerobic and coryneform identification card. Of 235 patients, 179 (76.2%) had malignancy. Among 90 (38.3%) patients with invasive actinomycosis, A odontolyticus was isolated in 32 (35.6%), followed by A meyeri in 20 (22.2%), and A naeslundii in 17 (18.9%). Among 145 (61.7%) colonized patients, A odontolyticus was isolated in 67 (46.2%), followed by A naeslundii in 27 (18.6%). Abdominopelvic infection was the most common site for invasive actinomycosis documented in 54 patients (60.0%) followed by orocervicofacial in 14 (15.6%) and thoracic in 10 (11.1%). A odontolyticus, A meyeri, and A naeslundi were the most frequently isolated species causing invasive actinomycosis, and A odontolyticus and A nauslendii among colonizers. Abdominopelvic represented the most frequent site for invasive disease. Further studies are needed to investigate the epidemiology of Actinomyces species in this population.

Exceptionally rare site:the occurrence of pilomatricoma of the ear lobule

Pilomatricoma, a rare benign tumor primarily affecting the head and neck region, presents diagnostic challenges and requires histopathological confirmation for accurate diagnosis. A case of pilomatricoma in a 70-year-old female with a chronic swelling on the Left ear lobule is reported. Surgical excision was performed, confirming the diagnosis histopathologically, highlighting the importance of accurate recognition and management. Timely surgical excision of pilomatricoma is crucial, with low recurrence rates reported. Accurate diagnosis aids in appropriate management and optimal patient outcomes.

Diagnostic Performance of Unstimulated IFN-γ (IRISA-TB) for Pleural Tuberculosis: A Prospective Study in South Africa and India.

Tuberculous pleural effusion (TPE) is the most common form of extrapulmonary tuberculosis in many settings. The diagnostic performance of the frontline polymerase chain reaction-based GeneXpert MTB/RIF Ultra (Xpert Ultra) remains suboptimal (sensitivity of ∼30%), but data are limited. Improved diagnostic approaches are urgently needed to detect extrapulmonary tuberculosis (EPTB) in tuberculosis (TB)-endemic settings. This multicenter, prospective cohort study evaluated the diagnostic performance of a rapid (same-day) interferon gamma rapid immunosuspension assay (IRISA-TB) in patients with presumed TPE from South Africa and India. Participants underwent pleural biopsy, and testing with other available same-day diagnostic assays (adenosine deaminase [ADA], Xpert Ultra, and IRISA-TB) was concurrently undertaken. The reference standard for TB was microbiological and/or histopathological confirmation using pleural fluid and/or pleural biopsy samples. A total of 217 participants with presumed TPE were recruited (106 from South Africa, 111 from India). The sensitivity of IRISA-TB (cut-point 20.5 pg/mL) was significantly better than that of Xpert Ultra (81.8% [70.4-90.2] vs 32.9% [22.1-45.1]; P < .001) and ADA at the 40 IU/mL cut-point used in India (81.8% [70.4-90.2] vs 53.8% [41.0-66.3]; P = .002). Compared with ADA at the 30 IU/mL cut-point used in South Africa, IRISA-TB had a higher specificity (96.6% [90.3-99.3] vs 87.1% [78.6-93.2]) and a higher positive predictive value (94.7% [85.5-97.3] vs 81.8% [72.4-88.5]). The negative predictive value (NPV; rule-out value) of IRISA-TB was significantly better than that of Xpert Ultra (87.5% [83.2-93.0] vs 64.9% [61.1-68.6]; P < .001) and ADA at the 40 IU/mL cut-point (87.5% [83.2-93.0] vs 74.1% [68.7-79.0]; P < .001). IRISA-TB demonstrated markedly better sensitivity and NPV than Xpert Ultra and excellent specificity for the diagnosis of TPE. These data have implications for clinical practice in TB-endemic settings.

Ocular Sarcoidosis as Initial Presentation of the Disease: Clinical Characteristics and Risk Factors Associated with Disease Recurrence

ABSTRACT Purpose To review the clinical presentation and diagnostic workup of patients presenting with ocular sarcoidosis as initial manifestation of the disease and identify risk factors for disease recurrence. Methods All cases of sarcoidosis followed in our departments of Ophthalmology and Internal Medicine were retrospectively reviewed. Among 177 patients, 50 had ocular sarcoidosis as initial presentation of the disease. Clinical, biological, radiological, and treatment data were collected. Logistic regression analysis was conducted to identify risk factors for recurrence. Results Mean age of patients was 51 years, with an equal M/F ratio. Bilateral ocular involvement was present in 86% of cases, with granulomatous panuveitis being the most common manifestation (48%). Two-thirds of patients had extraocular symptoms related to the disease, mostly fatigue. The most frequently involved extraocular site was the supradiaphragmatic lymph nodes, identified in 84% of cases. CRP was normal in 68% of patients, while ACE and lysozyme were elevated in 19% and 64% of cases, respectively. Histopathological confirmation was obtained in 68% of patients. Female sex (odds ratio [OR] 6.66, 95% confidence interval [CI] 1.50–40.40, p = 0.021) and granulomatous panuveitis (OR 7.23, 95% CI 1.70–40.99, p = 0.013) were identified as significant risk factors for disease recurrence. Conclusion Ocular sarcoidosis is a common initial presentation of systemic sarcoidosis. Diagnosis should be suspected in the presence of bilateral granulomatous panuveitis. Chest CT scan or 18F-FDG PET/CT is mandatory for systemic workup and biopsy is necessary for definite diagnosis. Female sex and a panuveitis presentation are significantly associated with disease recurrence.

Psychological impact of Placenta Accreta Spectrum disorders (PAS) and risk of Post-Traumatic Stress Disorder (PTSD): A cross-sectional study

ObjectivePlacenta Accreta Spectrum disorders (PAS) are a group of obstetric complications with an increasing incidence. The high maternal and neonatal morbidity and mortality associated with PAS leads to concerns about the negative psychological impact, and even the risk of developing Post-Traumatic Stress Disorder (PTSD). The aim of this study was to assess the psychological impact of PAS diagnosis and intervention during pregnancy and postpartum and its potential association with PTSD.STUDY DESIGN: A cross-sectional study was conducted, including cases of PAS FIGO grade 2 and 3 treated at University Hospital Center São João, between 2010–2023. Only cases with histopathological confirmation after peripartum hysterectomy were included. Data were obtained from electronic medical records (Sclinic® and Obscare®). The impact of Event Scale – Revised (IES-R), a validated questionnaire, was applied, after surgery for PAS, to assess the psychological impact of PAS diagnosis and treatment. ResultsFourteen cases of PAS were identified. The mean maternal age was 36.8 years. Approximately 86 % of cases had antenatal suspicion. The mean gestational age at delivery was 34 weeks. Of the 14 women, only 11 responded to the request to participate in the study (7 interviewed in person and 4 remotely). Four women had IES-R scores indicative of high risk of PTSD (IES-R>33 points), one had an intermediate risk (IES-R between 24–32 points), and 6 fell into the low-risk category. The mean score was 22.4 points. The analysis of IES-R results by clusters showed higher scores in the intrusion category, which relates to intrusive and unwanted thoughts, images and memories. ConclusionGiven the high morbidity and mortality described in women with PAS, the risk of PTSD should be acknowledged, motivating early intervention to prevent the development of severe and potentially chronic symptoms. Supportive measures and psychiatric and/or psychological follow-up should be promptly implemented, ideally by multidisciplinary teams.

Role of FNAC in Breast Lump and its Histopathological Correlation

Introduction: Breast malignancy is one of the common causes of morbidity and mortality among females. Screening of breast lumps by Fine Needle Aspiration Cytology (FNAC) is included in triple approach and is easy to perform. Accuracy of diagnosis can be further enhanced by histopathological confirmation. Aims: The role of FNAC in diagnosis of breast lumps and to determine its diagnostic accuracy. Methods: This was a hospital based prospective study conducted over the period of one year (from March 2023 to February 2024) in department of Pathology, Nepalgunj Medical College, Kohalpur, Nepal. Patients who presented with breast lump underwent FNAC with biopsy for histopathological study was included in the study. Cytological opinion was categorized according to International Academy of Cytology Yokohama System for Reporting Breast Fine Needle Aspiration Biopsy Cytopathology criteria reporting system. Histological correlation was carried out in patients who went surgical excision or biopsy of the lesion. Results: Most common diagnosis on cytology was fibroadenoma. According to International Academy of Cytology Yokohama reporting system C2 (benign) was most common reported category (19 cases). On histopathological study, 19 cases were benign and 13 cases were malignant with most common benign lesion being fibroadenoma and all malignant cases were Invasive ductal carcinoma. All cases diagnosed as malignant on cytology were concordant on histopathology. Three benign, one atypical and one suspicious on cytology were malignant on histopathological study. The sensitivity and specificity of FNAC was 84.2% and 69.2% respectively. Diagnostic accuracy of FNAC was 59.4%. Conclusion: Breast FNAC is a rapid and reliable tool for evaluation and have high sensitivity and specificity.

Step-by-step Stereotactic Radiotherapy Planning of Pituitary Adenoma: A ROSE (Radiation Oncology from Simulation to Execution) Guide to Radiation Oncologists

Introduction Pituitary adenoma accounts for 10%–20% of all intracranial malignancies. The primary modality of treatment is surgery, while pituitary radiation is indicated in residual or recurrent setting post-surgery. Currently, stereotactic radiotherapy (SRT) is one of the main modalities of radiation treatment. The objective of this article is to describe the procedural steps for radiation planning of SRT of pituitary adenoma Methods The step-by-step procedure for stereotactic planning of pituitary adenoma has been described using a clinical scenario of pituitary adenoma. Results The stereotactic radiation planning of pituitary adenoma starts with the basic history and relevant clinical evaluation that is visual testing. Magnetic resonance imaging (MRI) of the brain is the imaging modality of choice. Evaluation of surgical notes and post-operative histopathology confirmation of diagnosis should also be done. The radiation planning of pituitary adenoma starts with Computed tomography (CT) simulation and MRI of brain that should be done in prescribed format to achieve uniformity in radiation planning. After CT and MRI image fusion, contouring of target, organs at risk (OAR) and radiation planning should be done. The plan evaluation includes target and OAR coverage index, conformity, homogeneity and gradient index and beam arrangement. After radiation plan evaluation, treatment is delivered after quality assurance and dry run. Conclusion The article highlights the sequential process of radiation planning for SRT—starting from simulation, planning, evaluation of plan and treatment.

Navigating the Diagnosis and Treatment of Extra-Adrenal Pheochromocytoma Presenting with Chronic Abdominal Pain: A Clinical Conundrum

Background: Extra-adrenal pheochromocytomas, or paragangliomas, are rare neuroendocrine tumors that present diagnostic challenges due to their nonspecific symptoms and radiologic features.Objective: To report a case of extra-adrenal pheochromocytoma presenting as chronic abdominal pain and hepatic masses, emphasizing the diagnostic and therapeutic challenges.Methods: A 36-year-old male with a history of diabetes and hypertension presented with weight loss and abdominal pain. Initial evaluation included comprehensive physical examination, laboratory tests, ultrasonography, and CT imaging of the abdomen and chest. Partial hepatectomy was performed, and the diagnosis was confirmed through histopathological and immunohistochemical analysis.Results: Imaging identified three mixed echogenic hepatic masses, with the largest measuring 5.6 x 5.4 cm. Enlarged para-aortic lymph nodes were observed, the largest being 4.0 x 3.5 cm. CT chest revealed a mass on the chest wall (7.0 x 3.0 cm) with metastatic lung nodules. Immunohistochemistry confirmed paraganglioma with positivity for chromogranin A and neuron-specific enolase.Conclusion: This case underscores the importance of considering paragangliomas in differential diagnoses of atypical abdominal masses and highlights the critical role of histopathological confirmation in guiding management.

Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial

At the first interim analysis of the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study, the addition of pembrolizumab to chemoradiotherapy provided a statistically significant and clinically meaningful improvement in progression-free survival in patients with locally advanced cervical cancer. We report the overall survival results from the second interim analysis of this study. Eligible patients with newly diagnosed, high-risk (FIGO 2014 stage IB2-IIB with node-positive disease or stage III-IVA regardless of nodal status), locally advanced, histologically confirmed, squamous cell carcinoma, adenocarcinoma, or adenosquamous cervical cancer were randomly assigned 1:1 to receive five cycles of pembrolizumab (200 mg) or placebo every 3 weeks with concurrent chemoradiotherapy, followed by 15 cycles of pembrolizumab (400 mg) or placebo every 6 weeks. Pembrolizumab or placebo and cisplatin were administered intravenously. Patients were stratified at randomisation by planned external beam radiotherapy type (intensity-modulated radiotherapy [IMRT] or volumetric-modulated arc therapy [VMAT] vs non-IMRT or non-VMAT), cervical cancer stage at screening (FIGO 2014 stage IB2-IIB node positive vs III-IVA), and planned total radiotherapy (external beam radiotherapy plus brachytherapy) dose (<70 Gy vs ≥70 Gy [equivalent dose of 2 Gy]). Primary endpoints were progression-free survival per RECIST 1.1 by investigator or by histopathological confirmation of suspected disease progression and overall survival defined as the time from randomisation to death due to any cause. Safety was a secondary endpoint. Between June 9, 2020, and Dec 15, 2022, 1060 patients at 176 sites in 30 countries across Asia, Australia, Europe, North America, and South America were randomly assigned to treatment, with 529 patients in the pembrolizumab-chemoradiotherapy group and 531 patients in the placebo-chemoradiotherapy group. At the protocol-specified second interim analysis (data cutoff Jan 8, 2024), median follow-up was 29·9 months (IQR 23·3-34·3). Median overall survival was not reached in either group; 36-month overall survival was 82·6% (95% CI 78·4-86·1) in the pembrolizumab-chemoradiotherapy group and 74·8% (70·1-78·8) in the placebo-chemoradiotherapy group. The hazard ratio for death was 0·67 (95% CI 0·50-0·90; p=0·0040), meeting the protocol-specified primary objective. 413 (78%) of 528 patients in the pembrolizumab-chemoradiotherapy group and 371 (70%) of 530 in the placebo-chemoradiotherapy group had a grade 3 or higher adverse event, with anaemia, white blood cell count decreased, and neutrophil count decreased being the most common adverse events. Potentially immune-mediated adverse events occurred in 206 (39%) of 528 patients in the pembrolizumab-chemoradiotherapy group and 90 (17%) of 530 patients in the placebo-chemoradiotherapy group. This study is registered with ClinicalTrials.gov, NCT04221945. Pembrolizumab plus chemoradiotherapy significantly improved overall survival in patients with locally advanced cervical cancer These data, together with results from the first interim analysis, support this immuno-chemoradiotherapy strategy as a new standard of care for this population. Merck Sharp & Dohme, a subsidiary of Merck & Co.

Comprehensive Evaluation of Pulmonary Masses Using Multi-detector CT: Correlating Morphological Features With CT-Guided Histopathological Findings for Enhanced Diagnostic Accuracy.

Lung masses pose a significant diagnostic challenge due to their diverse causes, from benign hamartomas to malignant bronchogenic carcinoma. Multi-detector CT (MDCT) is essential in evaluating these masses, offering detailed morphological insights to help differentiate between benign and malignant lesions. However, a definitive diagnosis often requires histopathological confirmation. CT-guided biopsy is crucial, providing a minimally invasive method to obtain tissue samples and thus guiding clinical management and treatment decisions. The primary objective of this study was to assess the diagnostic accuracy of MDCT in differentiating between benign and malignant lung mass lesions. The study focused on evaluating the characteristic features of lung masses on MDCT that aid in this differentiation, correlating imaging findings with histopathological results from CT-guided biopsies, and determining the overall diagnostic utility of MDCT in thoracic lesions. This hospital-based observational study was conducted over a period of 17 months. The study included 52 patients with thoracic lesions, identified through imaging techniques such as chest radiographs and CT scans. These patients underwent CT-guided biopsy, with tissue samples sent for histopathological examination. Inclusion criteria involved patients with clinically and radiographically diagnosed lung masses, while exclusion criteria included those who did not consent, had contraindications to contrast media, or had conditions such as severe respiratory distress or coagulopathy. The data were analyzed using descriptive statistics, with efficacy measures such as yield and failure rates of CT-guided biopsies and validation measures like sensitivity, specificity, positive predictive value, and negative predictive value for MDCT. The study included 52 patients (50% male, 50% female), aged 16-80, with the most common age group being 51-60 years. Lesions were mainly in the lung parenchyma (65.38%), followed by the mediastinum (15.38%), hilar region (11.54%), and pleura (7.69%). MDCT evaluation classified 84.44% of the lesions as malignant, characterized by irregular contours, inhomogeneous texture, and contrast enhancement, while 15.55% were benign. Histopathology confirmed 42 malignant lesions, with squamous cell carcinoma being the most prevalent. Benign lesions included abscesses, tuberculosis, and pneumonitis. The study achieved a 100% success rate for CT-guided biopsy, with one minor complication (pneumothorax). The diagnostic accuracy of MDCT was notable, with a sensitivity of 100% for detecting malignancies, a specificity of 77.78%, a positive predictive value of 87.50%, and a negative predictive value of 100%, emphasizing its effectiveness in thoracic lesion evaluation. MDCT is a highly effective tool in the evaluation of lung masses, providing critical information that aids in distinguishing between benign and malignant lesions. When combined with CT-guided biopsy, it offers a reliable method for obtaining diagnostic tissue samples, with a high degree of accuracy and a low complication rate. The study underscores the importance of integrating imaging and histopathological findings in the management of thoracic lesions, ultimately enhancing diagnostic precision and informing appropriate clinical interventions.

[89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial

With limitations of conventional imaging and biopsy, accurate, non-invasive techniques to detect clear-cell renal cell carcinoma in patients with renal masses remain an unmet need. 89Zr-labelled monoclonal antibody ([89Zr]Zr-girentuximab) has high affinity for carbonic anhydrase 9, a tumour antigen highly expressed in clear-cell renal cell carcinoma. We aimed to evaluate [89Zr]Zr-girentuximab PET-CT imaging for detection and characterisation of clear-cell renal cell carcinoma. ZIRCON was a prospective, open-label, multicentre, phase 3 trial conducted at 36 research hospitals and practices across nine countries (the USA, Australia, Canada, the UK, Türkiye, Belgium, the Netherlands, Spain, and France). Patients aged 18 years or older with an indeterminate renal mass 7 cm or smaller (cT1) suspicious for clear-cell renal cell carcinoma and scheduled for nephrectomy received a single dose of [89Zr]Zr-girentuximab (37 MBq ±10%; 10 mg girentuximab) intravenously followed by abdominal PET-CT imaging 5 days (±2 days) later. Surgery was performed no later than 90 days after administration of [89Zr]Zr-girentuximab. Blinded central review, conducted by three independent readers, determined the histology from surgical samples. The coprimary endpoints, determined for each individual reader, were the sensitivity and specificity of [89Zr]Zr-girentuximab PET-CT imaging to detect clear-cell renal cell carcinoma, with histopathological confirmation as standard of truth. Analyses were on the full analysis set of patients, defined as patients who had evaluable PET-CT imaging and a confirmed histopathological diagnosis. The trial is registered with ClinicalTrials.gov, NCT03849118, and EUDRA Clinical Trials Register, 2018-002773-21, and is closed to enrolment. Between Aug 14, 2019, and July 8, 2022, 371 patients were screened for eligibility, 332 of whom were enrolled. 300 patients received [89Zr]Zr-girentuximab (214 [71%] male and 86 [29%] female). 284 (95%) evaluable patients were included in the primary analysis. The mean sensitivity was 85·5% (95% CI 81·5-89·6) and mean specificity was 87·0% (81·0-93·1). No safety signals were observed. Most adverse events were not or were unlikely to be related to [89Zr]Zr-girentuximab, with most (193 [74%] of 261 events) occurring during or after surgery. The most common grade 3 or worse adverse events were post-procedural haemorrhage (in six [2%] of 261 patients), urinary retention (three [1%]), and hypertension (three [1%]). In 25 (8%) of 300 patients, 52 serious adverse events were reported, of which 51 (98%) occurred after surgery. There were no treatment-related deaths. Our results suggest that [89Zr]Zr-girentuximab PET-CT has a favourable safety profile and is a highly accurate, non-invasive imaging modality for the detection and characterisation of clear-cell renal cell carcinoma, which has the potential to be practice changing. Telix Pharmaceuticals.

Challenges and Insights in the Diagnosis and Management of Orbital Tuberculosis: A Systematic Review of 113 Cases.

Orbital tuberculosis (O-TB) is an extremely rare manifestation of extra-pulmonary tuberculosis (TB), which affects orbital structures and causes very complex clinical scenarios that may simulate other pathologies affecting the orbit. Its diagnostic and therapeutic challenges are due to its rarity and lack of specificity on symptoms. This systematic review aims to give an in-depth analysis regarding the presentation of clinical features, diagnosis methods, treatment outcomes, and complications, enhancing the current understanding and management of O-TB.A systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Literature searches were conducted in PubMed and Scopus up to August 2024. The literature review included case series, case reports, and retrospective studies focusing on O-TB and involved a total of 113 cases from 12 studies. The extracted data were qualitatively synthesized regarding patient demographics, clinical presentations, diagnostic methods, treatment regimens, and the ensuing outcomes. The review found that O-TB mostly affects subjects with a mean age of 37.75 years, although there is a very wide age range of reported cases: 2-82 years with an almost equal gender distribution. The most common symptoms were vision impairment at71.68%, eyelid swelling at 9.73%, and exophthalmos at 5.31%. Imaging, especially with computed tomography (CT) scans in 60.18% of patients, along with histopathological confirmation and molecular biological confirmation positive in 46.02%, was the principal tool for diagnosis. In most cases, antitubercular therapy (ATT) was the mainstay of treatment, leading to complete resolution. However, 30.09% of these cases had some complications like glaucoma and cataracts that point to careful management and follow-up. O-TB still remains a diagnostic challenge due to its rarity and changing clinical presentations. Early diagnosis and identification, presently mainly through imaging and histopathological examination, is important for the management. This review shows the effectiveness of ATT in the treatment of O-TB but also brings out the need for better diagnostic facilities and uniformity in treatment protocols so that complications can be prevented and outcomes improved. Future studies must be directed toward the development of more sensitive diagnostic tools and the elucidation of immune responses in O-TB guiding better clinical practice.

FP4.4 - Everything is not always as it seems – Discordance between cross-sectional imaging and pathology. A case report

Abstract Cross-sectional imaging of colonic pathology is usually correlated with other investigations such as optical colonoscopy (OC) prior to surgical treatment. In situations such as acute inflammation, this is not possible and surgery is undertaken based on cross-sectional imaging without histopathological confirmation. This case reports describes a 78-year-old female who presented with progressive shortness of breath associated with fatigue and unintentional weight loss. Initial bloods demonstrated a normocytic anaemia (Hb 105g/L, MCV 86fl), raised D-dimer (3460ng/mL) and raised C-reactive protein (133mg/L) with normal white cell count (8.6 x109/L). An unprepared computed tomography (CT) of the abdomen and pelvis revealed extensive bowel thickening in the caecum with radiological appearances consistent with a primary caecal malignancy. Preoperative colonoscopy was not performed as suspicion of perforation on CT imaging precluded the use of mechanical bowel preparation. Preoperative optimisation of the patient was commenced and an elective right hemicolectomy performed. The patient had an uneventful post-operative recovery. Results on histopathology inspection revealed chronic xanthogranulomatous inflammation but no macroscopic or microscopic evidence of dysplasia or malignancy. There continues to be an emerging role for the use of CT imaging, especially CT colonography, in the investigation and diagnosis of CRC. However, difficulty in distinguishing between malignant and non-malignant inflammation on CT endorses the quintessential place of OC with biopsy as the definitive investigation of CRC, especially if suspicion of CRC on unprepared CT. Xanthogranulomatous inflammation should be considered by clinicians, radiologists and pathologists as a differential diagnosis when CRC is suspected clinically and radiologically, without biopsy confirmation.

"Amr Sign": A Case-Control Study Evaluating the Diagnostic Value of a New Clinical Sign in the Diagnosis of Acute Appendicitis.

Introduction Acute appendicitis, a prevalent cause of acute abdominal pain and a common indication for emergency surgery, presents a diagnostic challenge due to its diverse clinical presentation and variability in appendix location and symptoms. Traditional diagnostic approaches, including physical examination, clinical scoring systems, and imaging techniques, have limitations. This study introduces the "Amr sign," a new diagnostic indicator characterized by sudden reflex hyperextension of the neck upon palpation of the right iliac fossa, which is hypothesized to reflect local peritoneal irritation from an inflamed appendix. Methods We conducted a prospective observational study at Alwakra Hospital from November 2016 to January 2019 that included 195 patients aged 15 years and older with right iliac fossa pain and an Alvarado score of four or more. The "Amr sign" was evaluated alongside standard clinical examination and imaging results. Diagnostic accuracy was assessed via histopathological confirmation, which is the gold standard. Results The "Amr sign" had a sensitivity of 68.6% and a specificity of 67.3%. The positive predictive value (PPV) was 89%, whereas the negative predictive value (NPV) was 45%. Receiver operating characteristic (ROC) analysis revealed an area under the curve (AUC) of 0.679 for the "Amr sign" compared with 0.622 for the other imaging modalities, suggesting comparable diagnostic performance. The "Amr sign" demonstrated a higher likelihood ratio of a positive test (2.3) and a lower likelihood ratio of a negative test (0.46). Conclusion The "Amr sign" is a promising diagnostic tool for acute appendicitis, offering a simple, reliable, and quick test that can be performed by less experienced physicians. While its sensitivity and specificity are moderate, its high PPV suggests that it is particularly useful in confirming appendicitis. Further research and validation are needed to fully establish its role in clinical practice.

Neurološki simptom kao prvi znak kolorektalnog karcinoma

Aim: To present a rare case of a patient with an isolated brain metastasis from colorectal carcinoma in whom an extensive diagnostic workup failed to identify the primary tumour. Case report: A 73-year-old female patient was admitted to the Neurology Department due to weakness in the right side of her body. Imaging with multislice computed tomography (MSCT) and brain magnetic resonance (MR) confirmed an expansive lesion in the left frontal region with surrounding oedema. Radiological findings suggested either a metastasis or a high-grade primary glioma. As the diagnostic workup did not reveal the primary tumour, the patient was transferred to Clinical Hospital Dubrava for surgical treatment. An intracranial tumour resection was performed with a histopathological confirmation of colon carcinoma metastasis. Postoperative brain irradiation was administered. A positron emission tomography scan (PET) showed focal accumulation of radioisotopes without clear pathological substrate in the appendix and cecoascedent junction area. Repeated colonoscopy did not find any pathological mucosal changes. The patient declined systemic treatment. Overall survival was 11 months, in line with literature data. Conclusion: The diagnosis of brain metastases from colorectal carcinoma is very rare, and even rarer is the diagnosis of isolated brain metastases without extracranial progression, counting for &amp;lt;0.5%. Therapeutic options for brain metastases from colorectal carcinoma include surgery, radio-neurosurgery, stereotactic radiotherapy, and brain irradiation. In our opinion, diagnostic evaluation of the central nervous system in patients with colorectal carcinoma should be considered if the patient has neurological symptoms or if there is an increase in carcinoembryonic antigen (CEA) levels without signs of extracranial disease progression.

Diagnostic Value of Pericholedochal Hypointense Ring Sign in MRI T2W Images in Cases of Pancreatic Ductal Adenocarcinoma.

To determine the value of hypointense pericholedocal ring sign in magnetic resonance imaging (MRI) T2W sequence images in the diagnosis of pancreatic ductal adenocarcinoma (PDA). Retrospective observational study. Place and Duration of the Study: Department of Radiology, Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, Turkiye, from January 2016 and March 2022. Retrospective analysis of MRI scans was performed on 70 patients with postoperative histopathological confirmation of a diagnosis of periampullary cancer. The patients' demographic information, the results of their histopathological examinations, and the findings of their MRIs were recorded. The results of the MRI were statistically analysed and compared between the PDA and the non-PDA groups. The study included 43 (61.4%) male and 27 (38.5%) female patients, with a mean age of 62.2 ± 8.4 years. The means of Wirsung diameter and tumour diameter were significantly higher in PDA group (p = 0.034, p = 0.010, respectively). A progressive contrast enhancement pattern of 95.3% was observed in PDA group, while 40.7% rapid contrast enhancement pattern was observed in the non-PDA group. Hypointense pericholedochal ring sign, observed in T2W sequences, was detected in 74.2% (n = 32) of the PDA group and 11.1% (n = 3) of the non-PDA group, and the findings were statistically significant (p <0.001). Hypointense pericholedochal ring sign in axial T2W sequences in periampullary tumours is a complementary MRI finding in the distinction between the PDA and the non-PDA groups. Magnetic resonance imaging, Pancreatic ductal adenocarcinoma, Periampullary tumours, Pericholedochal ring sign.

Donor-derived cell-free DNA is a valuable monitoring tool after single lung transplantation: Multicenter analysis

Donor-derived cell-free DNA (dd-cfDNA) is a nonspecific plasma biomarker for tissue injury which has been validated for monitoring of acute rejection (AR) after lung transplantation (LT). However, no studies to date have focused specifically on single lung transplantation (SLT). Herein we report the performance of dd-cfDNA in detecting AR in SLT from six academic centers who implemented this biomarker surveillance in their standard of practice (SOP). Dd-cfDNA test results were corrected for SLT by an algorithm in the CLIA-laboratory to permit comparison against the same 1.0% threshold used in double-lung transplant. Investigators reviewed patient SOP EMR clinical data to assign test results into cohorts based on clinical allograft health status. To avoid ambiguity in interpretation, samples drawn after a prior acute rejection or infection event or without histopathologic confirmation of acute rejection, were excluded from further analysis. Diagnostic cohorts included: Acute Rejection (AR, N=25 samples), healthy (STABLE, N=137), allograft-related Infection (INFXN, N=41), Chronic Lung Allograft Dysfunction (CLAD, N=7), and “OTHER” (N=12) types of graft injury. The study included a total of 257 dd-cfDNA results from 103 SLT patients while one patient was excluded due to active cancer. Samples were drawn a median of 233 days (IQR: 96-489) after SLT. Analysis of laterality for SLT (R vs L) and median dd-cfDNA fraction in AR and STABLE cohort was not statistically different. The median dd-cfDNA fraction was elevated with AR (1.8%) and INFXN (1.1%) vs STABLE (0.46%; p<0.0001). dd-cfDNA with CLAD was also significantly higher than STABLE cohort (p=0.0155). The Area Under Receiver Operator Characteristics (AUROC) Curve was 0.850 (95% CI: 0.72 - 0.95, p<0.0001) for AR vs STABLE cohort. Applying the dd-cfDNA threshold ≥ 1.0% for AR, yielded a Sensitivity= 77.8%, Specificity= 84.6%, Positive (PPV)= 38.31%, and Negative Predictive Value (NPV)= 96.83%. These multi-center data, incorporating real-world experiences, support the clinical validity and utility of dd-cfDNA monitoring of SLT recipients. Additional studies of the impact of biomarker surveillance on clinically meaningful outcomes should be forthcoming from robust, prospective, clinical trials already in progress.